Subcutaneous immunoglobulin (SCIG) ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
11	Myasthenia gravis	2

11. Myasthenia gravis

---

Clinical trials : 315 /  Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04728425 (ClinicalTrials.gov)	August 28, 2020	14/7/2020	Subcutaneous Immunoglobulin for Myasthenia Gravis	Efficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia Gravis	Myasthenia Gravis	Drug: subcutaneous immunoglobulin (SCIG);Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)	University Health Network, Toronto	NULL	Recruiting	18 Years	100 Years	All	30	Phase 2	Canada
2	NCT02100969 (ClinicalTrials.gov)	May 2015	27/3/2014	Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis	Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis	Myasthenia Gravis	Drug: HIZENTRA ®	Mazen Dimachkie, MD	CSL Behring	Completed	18 Years	N/A	All	23	Phase 2	United States;Canada